MA54526A - NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta - Google Patents
NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBetaInfo
- Publication number
- MA54526A MA54526A MA054526A MA54526A MA54526A MA 54526 A MA54526 A MA 54526A MA 054526 A MA054526 A MA 054526A MA 54526 A MA54526 A MA 54526A MA 54526 A MA54526 A MA 54526A
- Authority
- MA
- Morocco
- Prior art keywords
- polymorphic forms
- new polymorphic
- tgfbeta inhibitor
- tgfbeta
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
- C07D213/18—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782411P | 2018-12-20 | 2018-12-20 | |
| US201962930170P | 2019-11-04 | 2019-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54526A true MA54526A (fr) | 2022-03-30 |
Family
ID=69159846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054526A MA54526A (fr) | 2018-12-20 | 2019-12-17 | NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20200199104A1 (fr) |
| EP (1) | EP3898591A1 (fr) |
| JP (1) | JP2022513925A (fr) |
| KR (1) | KR20210104808A (fr) |
| CN (1) | CN113272279A (fr) |
| AU (1) | AU2019404250B2 (fr) |
| BR (1) | BR112021010577A2 (fr) |
| CA (1) | CA3123829A1 (fr) |
| CL (1) | CL2021001602A1 (fr) |
| CO (1) | CO2021007875A2 (fr) |
| CR (1) | CR20210334A (fr) |
| EC (1) | ECSP21044734A (fr) |
| IL (1) | IL284226A (fr) |
| MA (1) | MA54526A (fr) |
| MX (1) | MX2021007251A (fr) |
| PE (1) | PE20211756A1 (fr) |
| PH (1) | PH12021551459A1 (fr) |
| PY (1) | PY19106776A (fr) |
| SG (1) | SG11202105763SA (fr) |
| TW (1) | TWI743631B (fr) |
| UY (1) | UY38517A (fr) |
| WO (1) | WO2020128850A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3953357T1 (sl) | 2019-04-12 | 2024-08-30 | Blueprint Medicines Corporation | Pirolotriazinski derivati za zdravljenje bolezni, posredovanih s KIT in PDGFRA |
| WO2022130206A1 (fr) * | 2020-12-16 | 2022-06-23 | Pfizer Inc. | POLYTHÉRAPIES À INHIBITEURS DE TGFβR1 |
| CN112843058A (zh) * | 2021-01-27 | 2021-05-28 | 复旦大学附属华山医院 | 烟酰胺类化合物在制备治疗抗脊索肿瘤药物中的应用 |
| WO2022229846A1 (fr) * | 2021-04-29 | 2022-11-03 | Pfizer Inc. | Traitement du cancer à l'aide d'un inhibiteur du récepteur du facteur de croissance transformant bêta de type 1 |
| WO2024229406A1 (fr) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Polythérapie pour une maladie ou un trouble lié à ras |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (fr) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (fr) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras |
| WO2025265060A1 (fr) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Compositions thérapeutiques et procédés de gestion d'effets liés au traitement |
| WO2026006747A1 (fr) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026015801A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble liés à ras |
| WO2026015825A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas |
| WO2026015790A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015796A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026050446A1 (fr) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| CN120114413B (zh) * | 2025-03-17 | 2025-11-21 | 珠海市人民医院 | 一种pH-超声双响应白蛋白纳米药物及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE050761T2 (hu) * | 2014-01-01 | 2021-01-28 | Medivation Tech Llc | Vegyületek és alkalmazási eljárások |
-
2019
- 2019-12-17 CA CA3123829A patent/CA3123829A1/fr active Pending
- 2019-12-17 MA MA054526A patent/MA54526A/fr unknown
- 2019-12-17 JP JP2021534623A patent/JP2022513925A/ja not_active Withdrawn
- 2019-12-17 EP EP19835785.7A patent/EP3898591A1/fr not_active Withdrawn
- 2019-12-17 WO PCT/IB2019/060944 patent/WO2020128850A1/fr not_active Ceased
- 2019-12-17 CN CN201980086144.4A patent/CN113272279A/zh active Pending
- 2019-12-17 PH PH1/2021/551459A patent/PH12021551459A1/en unknown
- 2019-12-17 US US16/716,696 patent/US20200199104A1/en not_active Abandoned
- 2019-12-17 BR BR112021010577-8A patent/BR112021010577A2/pt not_active Application Discontinuation
- 2019-12-17 PE PE2021000893A patent/PE20211756A1/es unknown
- 2019-12-17 SG SG11202105763SA patent/SG11202105763SA/en unknown
- 2019-12-17 AU AU2019404250A patent/AU2019404250B2/en not_active Ceased
- 2019-12-17 KR KR1020217022254A patent/KR20210104808A/ko not_active Withdrawn
- 2019-12-17 MX MX2021007251A patent/MX2021007251A/es unknown
- 2019-12-17 CR CR20210334A patent/CR20210334A/es unknown
- 2019-12-18 UY UY0001038517A patent/UY38517A/es not_active Application Discontinuation
- 2019-12-19 TW TW108146622A patent/TWI743631B/zh not_active IP Right Cessation
- 2019-12-20 PY PY201919106776A patent/PY19106776A/es unknown
-
2021
- 2021-06-16 CO CONC2021/0007875A patent/CO2021007875A2/es unknown
- 2021-06-17 CL CL2021001602A patent/CL2021001602A1/es unknown
- 2021-06-18 EC ECSENADI202144734A patent/ECSP21044734A/es unknown
- 2021-06-20 IL IL284226A patent/IL284226A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3898591A1 (fr) | 2021-10-27 |
| KR20210104808A (ko) | 2021-08-25 |
| TWI743631B (zh) | 2021-10-21 |
| PE20211756A1 (es) | 2021-09-07 |
| ECSP21044734A (es) | 2021-07-30 |
| CR20210334A (es) | 2021-07-14 |
| CN113272279A (zh) | 2021-08-17 |
| CO2021007875A2 (es) | 2021-07-19 |
| WO2020128850A1 (fr) | 2020-06-25 |
| MX2021007251A (es) | 2021-07-15 |
| AU2019404250A1 (en) | 2021-07-01 |
| IL284226A (en) | 2021-08-31 |
| CL2021001602A1 (es) | 2022-01-21 |
| AU2019404250B2 (en) | 2022-12-22 |
| CA3123829A1 (fr) | 2020-06-25 |
| SG11202105763SA (en) | 2021-07-29 |
| US20200199104A1 (en) | 2020-06-25 |
| BR112021010577A2 (pt) | 2021-08-24 |
| JP2022513925A (ja) | 2022-02-09 |
| TW202039462A (zh) | 2020-11-01 |
| PH12021551459A1 (en) | 2022-04-11 |
| PY19106776A (es) | 2021-06-16 |
| UY38517A (es) | 2020-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54526A (fr) | NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta | |
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| EP3843704A4 (fr) | Formulations d'émulsion d'inhibiteurs de multikinase | |
| MA54901A (fr) | Inhibiteur de 15-pgdh | |
| MA51066A (fr) | Inhibiteurs d'intégrine | |
| EP4125884A4 (fr) | Combinaisons d'inhibiteurs d'eif4a | |
| EP3924352A4 (fr) | Formes cristallines d'un inhibiteur rsk | |
| EP4434979A4 (fr) | Inhibiteur de kif18a | |
| MA51819A (fr) | Nouvelles formes cristallines | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| DK4051688T3 (da) | Cd73-hæmmere | |
| MA54458A (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
| EP3856164A4 (fr) | Formes morphiques d'inhibiteurs du facteur d du complément | |
| EP3619208C0 (fr) | Formes cristallines d'un composé inhibiteur de jak | |
| EP3870181A4 (fr) | Formes cristallines d'un inhibiteur d'alk2 | |
| EP3532240A4 (fr) | Base d'outillage | |
| MA55801A (fr) | Formes solides d'un inhibiteur de glyt1 | |
| EP3917380C0 (fr) | Évaluation de la progression de la maladie de huntington | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| EP3992176A4 (fr) | Antagoniste d'ep2 | |
| EP3402521A4 (fr) | Inhibition de réaction allergique à l'aide d'un inhibiteur d'il-33 | |
| EP3870179A4 (fr) | Inhibition d'usp7 | |
| EP4003986A4 (fr) | Composés inhibiteurs |